Ind-Swift Lab.
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
April 7 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES - TRIBUNAL REJECTED ALL CLAIMS OF PI INDUSTRIES, COUNTERCLAIMS OF CO, OTHERS
IND SWIFT LABORATORIES - ARBITRATION PROCEEDINGS STAND CONCLUDED WITH NIL FINANCIAL IMPACT ON CO
Source text: ID:nBSE5Q8Ks8
Further company coverage: ISLB.NS
(([email protected];))
April 7 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES - TRIBUNAL REJECTED ALL CLAIMS OF PI INDUSTRIES, COUNTERCLAIMS OF CO, OTHERS
IND SWIFT LABORATORIES - ARBITRATION PROCEEDINGS STAND CONCLUDED WITH NIL FINANCIAL IMPACT ON CO
Source text: ID:nBSE5Q8Ks8
Further company coverage: ISLB.NS
(([email protected];))
Feb 16 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD - TO INVEST 400 MILLION RUPEES IN SAMBA FACILITY UPGRADE
Source text: ID:nBSE2RdDbC
Further company coverage: ISLB.NS
(([email protected];))
Feb 16 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD - TO INVEST 400 MILLION RUPEES IN SAMBA FACILITY UPGRADE
Source text: ID:nBSE2RdDbC
Further company coverage: ISLB.NS
(([email protected];))
IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD - APPROVES SHORT-TERM ADVANCE OF UP TO 200 MILLION RUPEES
Source text: ID:nBSEbdl2jw
Further company coverage: ISLB.NS
IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD - APPROVES SHORT-TERM ADVANCE OF UP TO 200 MILLION RUPEES
Source text: ID:nBSEbdl2jw
Further company coverage: ISLB.NS
Jan 1 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD -COMPLETES LAND PURCHASE FOR 177.2 MILLION RUPEES
Source text: ID:nNSE1pzGDw
Further company coverage: ISLB.NS
(([email protected];))
Jan 1 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD -COMPLETES LAND PURCHASE FOR 177.2 MILLION RUPEES
Source text: ID:nNSE1pzGDw
Further company coverage: ISLB.NS
(([email protected];))
June 27 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED PREFERENTIAL ISSUE OF UP TO 26 MILLION WARRANTS TO PROMOTER & PROMOTER GROUP AND NONPROMOTER CATEGORY
Further company coverage: ISLB.NS
(([email protected];))
June 27 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED PREFERENTIAL ISSUE OF UP TO 26 MILLION WARRANTS TO PROMOTER & PROMOTER GROUP AND NONPROMOTER CATEGORY
Further company coverage: ISLB.NS
(([email protected];))
June 24 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
TO CONSIDER AND APPROVE PROPOSAL FOR RAISING OF FUNDS
Source text for Eikon: ID:nBSE8MZLxR
Further company coverage: ISLB.NS
(([email protected];;))
June 24 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
TO CONSIDER AND APPROVE PROPOSAL FOR RAISING OF FUNDS
Source text for Eikon: ID:nBSE8MZLxR
Further company coverage: ISLB.NS
(([email protected];;))
** Shares of Ind-Swift Laboratories ISLB.NS up 10.8% to 116.6 rupees
** Formulations maker posted March-quarter consolidated net profit from loss a year earlier
** Stock on track for best day since April 5
** YTD, stock up 12.6%
(Reporting by Varun Vyas in Bengaluru)
** Shares of Ind-Swift Laboratories ISLB.NS up 10.8% to 116.6 rupees
** Formulations maker posted March-quarter consolidated net profit from loss a year earlier
** Stock on track for best day since April 5
** YTD, stock up 12.6%
(Reporting by Varun Vyas in Bengaluru)
May 13 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES MARCH-QUARTER CONSOL NET PAT 2.39 BILLION RUPEES VERSUS LOSS 251.2 MILLION RUPEES
IND SWIFT LABORATORIES MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.93 BILLION RUPEES VERSUS 3.04 BILLION RUPEES
Source text for Eikon: ID:nBSE3MjntR
Further company coverage: ISLB.NS
(([email protected];))
May 13 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES MARCH-QUARTER CONSOL NET PAT 2.39 BILLION RUPEES VERSUS LOSS 251.2 MILLION RUPEES
IND SWIFT LABORATORIES MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.93 BILLION RUPEES VERSUS 3.04 BILLION RUPEES
Source text for Eikon: ID:nBSE3MjntR
Further company coverage: ISLB.NS
(([email protected];))
April 19 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED INCORPORATION OF UNIT IN DUBAI, UNITED ARAB EMIRATES
Source text for Eikon: ID:nBSE8hXp61
Further company coverage: ISLB.NS
(([email protected];))
April 19 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED INCORPORATION OF UNIT IN DUBAI, UNITED ARAB EMIRATES
Source text for Eikon: ID:nBSE8hXp61
Further company coverage: ISLB.NS
(([email protected];))
March 8 (Reuters) - Ind Swift Ltd INSW.NS:
APPROVED MODIFICATIONS IN SCHEME OF ARRANGEMENT FOR AMALGAMATION OF CO WITH IND SWIFT LABORATORIES
Source text for Eikon: ID:nBSE3lXVml
Further company coverage: INSW.NS
(([email protected];))
March 8 (Reuters) - Ind Swift Ltd INSW.NS:
APPROVED MODIFICATIONS IN SCHEME OF ARRANGEMENT FOR AMALGAMATION OF CO WITH IND SWIFT LABORATORIES
Source text for Eikon: ID:nBSE3lXVml
Further company coverage: INSW.NS
(([email protected];))
March 5 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD- APPROVING INVESTMENT OF 320 MILLION RUPEES TOWARDS SERIES A COMPULSORILY CONVERTIBLE DEBENTURES
IND SWIFT LABORATORIES LTD - APPROVED AMENDMENT TO TERMS OF AGREEMENT EXECUTED BY COMPANY AND SYNTHIMED
IND SWIFT LABORATORIES LTD- APPROVED INVESTMENT IN CCDS OF SYNTHIMED INSTEAD OF SHARES, CCPS
Source text for Eikon: ID:nBSE389qbM
Further company coverage: ISLB.NS
(([email protected];))
March 5 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD- APPROVING INVESTMENT OF 320 MILLION RUPEES TOWARDS SERIES A COMPULSORILY CONVERTIBLE DEBENTURES
IND SWIFT LABORATORIES LTD - APPROVED AMENDMENT TO TERMS OF AGREEMENT EXECUTED BY COMPANY AND SYNTHIMED
IND SWIFT LABORATORIES LTD- APPROVED INVESTMENT IN CCDS OF SYNTHIMED INSTEAD OF SHARES, CCPS
Source text for Eikon: ID:nBSE389qbM
Further company coverage: ISLB.NS
(([email protected];))
IND Swift Laboratories Ltd ISLB.NS:
CCI APPROVES PROPOSED ACQUISITION OF CERTAIN BUSINESS UNDERTAKINGS OF IND SWIFT LABORATORIES LTD AND ESSIX BIOSCIENCES LID BY SYNTHIMED LABS PVT LTD - GOVERNMENT STATEMENT
Source text for Eikon: [ID:]
Further company coverage: ISLB.NS
IND Swift Laboratories Ltd ISLB.NS:
CCI APPROVES PROPOSED ACQUISITION OF CERTAIN BUSINESS UNDERTAKINGS OF IND SWIFT LABORATORIES LTD AND ESSIX BIOSCIENCES LID BY SYNTHIMED LABS PVT LTD - GOVERNMENT STATEMENT
Source text for Eikon: [ID:]
Further company coverage: ISLB.NS
Nov 29 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
COLLABORATES WITH CSIR-IMTECH
Source text for Eikon: ID:nBSE3MVkgT
Further company coverage: ISLB.NS
(([email protected];;))
Nov 29 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
COLLABORATES WITH CSIR-IMTECH
Source text for Eikon: ID:nBSE3MVkgT
Further company coverage: ISLB.NS
(([email protected];;))
Sept 25 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED SCHEME OF ARRANGEMENT OF IND SWIFT WITH IND SWIFT LABORATORIES ON A GOING CONCERN BASIS
Source text for Eikon: ID:nBSE2z5szB
Further company coverage: ISLB.NS
(([email protected];;))
Sept 25 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED SCHEME OF ARRANGEMENT OF IND SWIFT WITH IND SWIFT LABORATORIES ON A GOING CONCERN BASIS
Source text for Eikon: ID:nBSE2z5szB
Further company coverage: ISLB.NS
(([email protected];;))
BENGALURU, Sept 6 (Reuters) - India's Ind-Swift Laboratories ISLB.NS said on Wednesday it would sell its active pharmaceuticals ingredients (API) and contract research and manufacturing services (CRAMS) business to Synthimed Labs in a deal with an enterprise value of 16.50 billion rupees ($198.50 million).
($1 = 83.1238 Indian rupees)
(Reporting by Ashish Chandra in Bengaluru; Editing by Savio D'Souza)
(([email protected]; +91 7982114624;))
BENGALURU, Sept 6 (Reuters) - India's Ind-Swift Laboratories ISLB.NS said on Wednesday it would sell its active pharmaceuticals ingredients (API) and contract research and manufacturing services (CRAMS) business to Synthimed Labs in a deal with an enterprise value of 16.50 billion rupees ($198.50 million).
($1 = 83.1238 Indian rupees)
(Reporting by Ashish Chandra in Bengaluru; Editing by Savio D'Souza)
(([email protected]; +91 7982114624;))
Aug 31 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED SALE OF PROPERTY OF CO AT MUMBAI AT TOTAL CONSIDERATION OF 27.5 MILLION RUPEES
Source text for Eikon: ID:nBSE7788L9
Further company coverage: ISLB.NS
(([email protected];;))
Aug 31 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED SALE OF PROPERTY OF CO AT MUMBAI AT TOTAL CONSIDERATION OF 27.5 MILLION RUPEES
Source text for Eikon: ID:nBSE7788L9
Further company coverage: ISLB.NS
(([email protected];;))
Aug 9 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
JUNE-QUARTER CONSOL NET PAT 172.4 MILLION RUPEES VERSUS PROFIT 198.8 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.1 BILLION RUPEES VERSUS 2.8 BILLION RUPEES
Source text for Eikon: ID:nBSE1hLKd4
Further company coverage: ISLB.NS
(([email protected];;))
Aug 9 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
JUNE-QUARTER CONSOL NET PAT 172.4 MILLION RUPEES VERSUS PROFIT 198.8 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.1 BILLION RUPEES VERSUS 2.8 BILLION RUPEES
Source text for Eikon: ID:nBSE1hLKd4
Further company coverage: ISLB.NS
(([email protected];;))
May 29 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
MARCH-QUARTER CONSOL NET LOSS AFTER TAX 240.8 MILLION RUPEES VERSUS LOSS 614.5 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.04 BILLION RUPEES VERSUS 3.07 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: ISLB.NS
(([email protected];;))
May 29 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
MARCH-QUARTER CONSOL NET LOSS AFTER TAX 240.8 MILLION RUPEES VERSUS LOSS 614.5 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.04 BILLION RUPEES VERSUS 3.07 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: ISLB.NS
(([email protected];;))
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Ind-Swift Lab. do?
Ind-Swift Laboratories Ltd, based in Chandigarh, India, is a global manufacturer of APIs, Intermediates, and formulations. Established in 1995, the company focuses on API manufacturing and is a key player in the Indian pharmaceutical industry.
Who are the competitors of Ind-Swift Lab.?
Ind-Swift Lab. major competitors are Sakar Healthcare, Fredun Pharma, Jagsonpal Pharma, Syncom Formulations, Lincoln Pharma, Indoco Remedies, Beta Drugs. Market Cap of Ind-Swift Lab. is ₹1,628 Crs. While the median market cap of its peers are ₹1,421 Crs.
Is Ind-Swift Lab. financially stable compared to its competitors?
Ind-Swift Lab. seems to be less financially stable compared to its competitors. Altman Z score of Ind-Swift Lab. is 5.26 and is ranked 6 out of its 8 competitors.
Does Ind-Swift Lab. pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Ind-Swift Lab. latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Ind-Swift Lab. allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Inventory
How strong is Ind-Swift Lab. balance sheet?
Balance sheet of Ind-Swift Lab. is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Ind-Swift Lab. improving?
No, profit is decreasing. The profit of Ind-Swift Lab. is ₹41.32 Crs for TTM, ₹250 Crs for Mar 2025 and ₹421 Crs for Mar 2024.
Is the debt of Ind-Swift Lab. increasing or decreasing?
Yes, The net debt of Ind-Swift Lab. is increasing. Latest net debt of Ind-Swift Lab. is -₹409.56 Crs as of Mar-26. This is greater than Mar-25 when it was -₹821.6 Crs.
Is Ind-Swift Lab. stock expensive?
Ind-Swift Lab. is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Ind-Swift Lab. is 39.64, while 3 year average PE is 8.16. Also latest EV/EBITDA of Ind-Swift Lab. is 41.33 while 3yr average is 951.
Has the share price of Ind-Swift Lab. grown faster than its competition?
Ind-Swift Lab. has given lower returns compared to its competitors. Ind-Swift Lab. has grown at ~7.63% over the last 8yrs while peers have grown at a median rate of 31.0%
Is the promoter bullish about Ind-Swift Lab.?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 42.99% and last quarter promoter holding is 39.5%.
Are mutual funds buying/selling Ind-Swift Lab.?
There is Insufficient data to gauge this.